EUCTR2018-004003-39-BE进行中（未招募）1 期
A stratified dual-arm open-label two-stage phase 2 trial of trametinib in patients with advanced pretreated BRAFV600 wild-type melanoma - Tra-Mel WT
Z Brussel0 个研究点目标入组 58 人开始时间: 2018年10月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. = 18 years of age.
- •2. Signed written informed consent.
- •3. Histologically confirmed advanced melanoma that is either stage III (unresectable) or stage IV (metastatic)
- •4. Absence of a BRAF V600 mutation as determined by a validated test
- •5. In case of mucosal or acral melanoma, absence of a cKIT mutation as determined by a validated test
- •6. Presence of archival melanoma tissue of possibility of new biopsy.
- •7. Subjects must have failed at least prior systemic treatment with immune checkpoint inhibitors: CTLA-4 blocking immune checkpoint inhibitors (ipilimumab or other experimental anti-CTLA-4 antibodies), PD-1 blocking immune checkpoint inhibitors (pembrolizumab, nivolumab or other experimental anti-PD-1 antibodies), PD-L1 blocking immune checkpoint inhibitors. Progression of disease per RECIST, version 1.1 (Eisenhauer et al. Eur J Cancer 2009) or per immune related response criteria (Wolchok et al, Clin Cancer Res 2009) must have been documented during this treatment. Patients who are not able to undergo such treatment are also eligible.
- •8. The presence of at least one measurable lesion per RECIST, version 1.1 (Eisenhauer et al. Eur J Cancer 2009)
- •9. Interval between the date of the last administration of prior therapy for melanoma and the date of recruitment:
- •a. = 12 weeks following the date of the first administration and = 4 weeks following the date of the last administration of an anti-CTLA-4-, PD-1- or PD-L1 blocking immune checkpoint inhibitor;
- •b. = 4 weeks following the date of the last administration of chemotherapy (= 6 weeks in case of a nitrosurea or mitomycin C containing regimen);
- •c. = 4 weeks following major surgery or extensive radiotherapy.
- •10. All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed on Table 1) must be = Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0; National Cancer Institute (NCI) 2009) at the time of recruitment.
- •11. Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
- •12. Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to recruitment and agree to use effective contraception throughout the treatment period, and for 16 weeks after the last dose of study treatment.
- •13. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from 14 days prior to administration of the first dose of study treatment, throughout the
- •treatment period, and for 16 weeks after the last dose of study treatment.
- •14. An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Oken et al, Am J Clin Oncol 1982).
- •15. Adequate baseline organ function as defined in Table 1.
- •Laboratory values
- •Hematologic
- •Absolute neutrophil count
- •= 1.2 x 103/mm3
- •= 9.0 g/dL
- •Platelet count
排除标准
- •1. Subjects with uveal melanoma.
- •2. Prior treatment with MAPK-pathway inhibitors (BRAF inhibitors, MEK inhibitors)
- •3. Subjects with clinically active brain metastases (lesions should be stable and have been definitely treated with stereotactic radiation therapy, surgery or gamma knife therapy with no evidence of disease progression prior to enrollment.
- •4. Any contra-indication for evaluation by whole body FDG-PET/CT and MRI of the brain.
- •5. History of another malignancy. Exception: subjects who have been disease-free for 3 years, (i.e. subjects with second malignancies that are indolent or definitively treated at least 3 years ago) or subjects with a history of completely resected non-melanoma skin cancer.
- •6. Current use of any prohibited medication.
- •7. Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days), whichever is shorter, prior to recruitment.
- •8. Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject’s safety, obtaining informed consent, or compliance with study procedures.
- •9. Known Human Immunodeficiency Virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted).
- •10. No enzyme inducing anticonvulsants for = 4 weeks prior to recruitment
- •11. A history or evidence of cardiovascular risk including any of the following:
- •a. Current LVEF < LLN
- •b. A QT interval corrected for heart rate using the Bazett’s formula (QTcB) = 480 msec;
- •c. A history or evidence of current clinically significant uncontrolled arrhythmias; exception: subjects with atrial fibrillation controlled for > 30 days prior to recruitment are eligible.
- •d. A history (within 6 months prior to recruitment) of acute coronary syndromes (including myocardial infarction or unstable angina), or coronary angioplasty;
- •e. A history or evidence of current = Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines;
- •f. Treatment refractory hypertension defined as a blood pressure of systolic >140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by antihypertensive therapy;
- •g. Patients with intra-cardiac defibrillators or permanent pacemakers;
- •h. Known cardiac metastases;
- •i. Abnormal cardiac valve morphology (= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
- •12. Uncorrectable electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia, hypocalcaemia), long QT syndrome or taking medicinal products known to prolong the QT interval.
- •13. A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) including:
- •a. Presence of predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosit
研究者
相似试验
尚未招募
2 期
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapyadvanced islet cell carcinomaadvanced pancreatic neuroendocrine tumor1002911210014713NL-OMON29869ovartis8
进行中（未招募）
不适用
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - NAPancreatic neuroendocrine tumors (NET) comprise only 1-2% of all pancreatic tumors. The annual incidence is approx. 3.5 to 4 per million population. The hormones secreted by pancreatic NET depend upon the cell of origin and are physiologically involved in a network of autocrine, paracrine, endocrine and neurotransmitter communication. While hormone secretion is not observed in all cases, the nonfunctioning” pancreatic NET tend to be more aggressive and present with symptoms of tumor bulk.EUCTR2006-001247-64-NLovartis Pharma Services AG144
进行中（未招募）
不适用
Safety/efficacy of Everolimus in adults with advanced pancreatic neuroendocrine cancer not responsive to chemotherapyAdvanced pancreatic neuroendocrine tumors (NET).MedDRA version: 14.1Level: LLTClassification code 10033630Term: Pancreatic islet cell neoplasm malignant NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-001247-64-SEovartis Pharma Services AG144
进行中（未招募）
1 期
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy. - NAPancreatic neuroendocrine tumors (NET) comprise only 1-2% of all pancreatic tumors. The annual incidence is approx. 3.5 to 4 per million population. The hormones secreted by pancreatic NET depend upon the cell of origin and are physiologically involved in a network of autocrine, paracrine, endocrine and neurotransmitter communication. While hormone secretion is not observed in all cases, the nonfunctioning” pancreatic NET tend to be more aggressive and present with symptoms of tumor bulk.EUCTR2006-001247-64-BEovartis Pharma Services AG144
进行中（未招募）
不适用
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapyEUCTR2006-001247-64-ESovartis Farmaceutica, S.A144